40 results on '"Giampà, Carmela"'
Search Results
2. Inhibition of phosphodiesterases rescues striatal long-term depression and reduces levodopa-induced dyskinesia
- Author
-
Picconi, Barbara, Bagetta, Vincenza, Ghiglieri, Veronica, Paillè, Vincent, Di Filippo, Massimiliano, Pendolino, Valentina, Tozzi, Alessandro, Giampà, Carmela, Fusco, Francesca R., Sgobio, Carmelo, and Calabresi, Paolo
- Published
- 2011
- Full Text
- View/download PDF
3. Phosphodiesterase type IV inhibition prevents sequestration of CREB binding protein, protects striatal parvalbumin interneurons and rescues motor deficits in the R6/2 mouse model of Huntingtonʼs disease
- Author
-
Giampà, Carmela, Middei, Silvia, Patassini, Stefano, Borreca, Antonella, Marullo, Fabrizia, Laurenti, Daunia, Bernardi, Giorgio, Ammassari-Teule, Martine, and Fusco, Francesca R.
- Published
- 2009
- Full Text
- View/download PDF
4. Distribution of TRPC1 receptors in dendrites of rat substantia nigra: a confocal and electron microscopy study
- Author
-
Martorana, Alessandro, Giampà, Carmela, DeMarch, Zena, Viscomi, Maria Teresa, Patassini, Stefano, Sancesario, Giuseppe, Bernardi, Giorgio, and Fusco, Francesca R.
- Published
- 2006
5. Striatal modulation of cAMP-response-element-binding protein (CREB) after excitotoxic lesions: implications with neuronal vulnerability in Huntingtonʼs disease
- Author
-
Giampà, Carmela, DeMarch, Zena, DʼAngelo, Vincenza, Morello, Maria, Martorana, Alessandro, Sancesario, Giuseppe, Bernardi, Giorgio, and Fusco, Francesca R.
- Published
- 2006
6. Co-localization of brain-derived neurotrophic factor (BDNF) and wild-type huntingtin in normal and quinolinic acid-lesioned rat brain
- Author
-
Fusco, Francesca R., Zuccato, Chiara, Tartari, Marzia, Martorana, Alessandro, De March, Zena, Giampà, Carmela, Cattaneo, Elena, and Bernardi, Giorgio
- Published
- 2003
7. Conditioned medium from amniotic cells protects striatal degeneration and ameliorates motor deficits in the R6/2 mouse model of Huntington's disease.
- Author
-
Giampà, Carmela, Alvino, Alessandra, Magatti, Marta, Silini, Antonietta R., Cardinale, Antonella, Paldino, Emanuela, Fusco, Francesca R., and Parolini, Ornella
- Subjects
HUNTINGTON disease ,MESENCHYMAL stem cells ,NEURODEGENERATION ,GENE expression ,MEDICAL care - Abstract
Inflammation significantly impacts the progression of Huntington's disease (HD) and the mutant HTT protein determines a pro‐inflammatory activation of microglia. Mesenchymal stem/stromal cells (MSC) from the amniotic membrane (hAMSC), and their conditioned medium (CM‐hAMSC), have been shown to possess protective effects in vitro and in vivo in animal models of immune‐based disorders and of traumatic brain injury, which have been shown to be mediated by their immunomodulatory properties. In this study, in the R6/2 mouse model for HD we demonstrate that mice treated with CM‐hAMSC display less severe signs of neurological dysfunction than saline‐treated ones. CM‐hAMSC treatment significantly delayed the development of the hind paw clasping response during tail suspension, reduced deficits in rotarod performance, and decreased locomotor activity in an open field test. The effects of CM‐hAMSC on neurological function were reflected in a significant amelioration in brain pathology, including reduction in striatal atrophy and the formation of striatal neuronal intranuclear inclusions. In addition, while no significant increase was found in the expression of BDNF levels after CM‐hAMSC treatment, a significant decrease of microglia activation and inducible nitric oxide synthase levels were observed. These results support the concept that CM‐hAMSC could act by modulating inflammatory cells, and more specifically microglia. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
8. Selective Sparing of Striatal Interneurons after Poly (ADP-Ribose) Polymerase 1 Inhibition in the R6/2 Mouse Model of Huntington's Disease.
- Author
-
Paldino, Emanuela, Cardinale, Antonella, D'Angelo, Vincenza, Sauve, Ilaria, Giampà, Carmela, and Fusco, Francesca R.
- Subjects
INTERNEURONS ,POLYMERASES ,HUNTINGTON disease ,TRANSGENIC mice ,CREB-binding protein ,PREVENTION - Abstract
Poly (ADP-ribose) polymerases (PARPs) are enzymes that catalyze ADP-ribose units transfer from NAD to their substrate proteins. It has been observed that PARP-1 is able to increase both post-ischemic and excitotoxic neuronal death. In fact, we have previously shown that, INO-1001, a PARP-1 inhibitor, displays a neuroprotective effect in the R6/2 model of Huntington's disease (HD). In this study, we investigated the effects of PARP-1-inhibition on modulation of phosphorylated c-AMP response element binding protein (pCREB) and CREB-binding protein (CBP) localization in the different striatal neuronal subsets. Moreover, we studied the neurodegeneration of those interneurons that are particularly vulnerable to HD such as parvalbuminergic and calretininergic, and of other subclasses of interneurons that are known to be resistant, such as cholinergic and somatostatinergic interneurons. Transgenic mice were treated with INO-1001 (10 mg/Kg daily) starting from 4 weeks of age. Double-label immunofluorescence was performed to value the distribution of CBP in ubiquitinated Neuronal intranuclear inclusions (NIIs) in the striatum. INO-1001-treated and saline-treated brain sections were incubated with: goat anti-choline acetyl transferase; goat anti-nitric oxide synthase; mouse anti-parvalbumin and mouse anti-calretinin. Morphometric evaluation and cell counts were performed. Our study showed that the PARP inhibitor has a positive effect in sparing parvalbumin and calretinin-containing interneurons of the striatum, where CREB was upregulated. Moreover, INO-1001 promoted CBP localization into the nuclei of the R6/2 mouse. The sum of our data corroborates the previous observations indicating PARP inhibition as a possible therapeutic tool to fight HD. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
9. Phosphodiesterase-10A Inverse Changes in Striatopallidal and Striatoentopeduncular Pathways of a Transgenic Mouse Model of DYT1 Dystonia.
- Author
-
D'angelo, Vincenza, Castelli, Valentina, Giorgi, Mauro, Cardarelli, Silvia, Saverioni, Ilaria, Palumbo, Francesca, Bonsi, Paola, Pisani, Antonio, Giampà, Carmela, Sorge, Roberto, Biagioni, Stefano, Fusco, Francesca R., and Sancesario, Giuseppe
- Subjects
BASAL ganglia diseases ,DOPAMINE receptors ,DYSTONIA ,HYPERKINETIC dysarthria ,PHOSPHODIESTERASE inhibitors ,PATIENTS ,THERAPEUTICS - Abstract
We report that changes of phosphodiesterase-10A (PDE10A) can map widespread functional imbalance of basal ganglia circuits in a mouse model of DYT1 dystonia overexpressing mutant torsinA. PDE10A is a key enzyme in the catabolism of second messenger cAMP and cGMP, whose synthesis is stimulated by D1 receptors and inhibited by D2 receptors preferentially expressed in striatoentopeducuncular/ substantia nigra or striatopallidal pathways, respectively. PDE10A was studied in control mice (NT) and in mice carrying human wild-type torsinA (hWT) or mutant torsinA (hMT). Quantitative analysis of PDE10A expression was assessed in different brain areas by rabbit anti-PDE10A antibody immunohistochemistry and Western blotting. PDE10A-dependent cAMP hydrolyzing activity and PDE10A mRNA were also assessed. Striatopallidal neurons were identified by rabbit anti-enkephalin antibody. In NT mice, PDE10A is equally expressed in medium spiny striatal neurons and in their projections to entopeduncular nucleus/substantia nigra and to external globus pallidus. In hMT mice, PDE10A content selectively increases in enkephalin-positive striatal neuronal bodies; moreover, PDE10A expression and activity in hMT mice, compared with NT mice, significantly increase in globus pallidus but decrease in entopeduncular nucleus/substantia nigra. Similar changes of PDE10A occur in hWT mice, but such changes are not always significant. However, PDE10A mRNA expression appears comparable among NT, hWT, and hMT mice. In DYT1 transgenic mice, the inverse changes of PDE10A in striatoentopeduncular and striatopallidal projections might result over time in an imbalance between direct and indirect pathways for properly focusing movement. The decrease of PDE10A in the striatoentopeduncular/nigral projections might lead to increased intensity and duration of D1-stimulated cAMP/cGMP signaling; conversely, the increase of PDE10A in the striatopallidal projections might lead to increased intensity and duration of D2-inhibited cAMP/cGMP signaling. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
10. Tryptanthrin Suppresses the Activation of the LPS-Treated BV2 Microglial Cell Line via Nrf2/HO-1 Antioxidant Signaling.
- Author
-
Young-Won Kwon, So Yeong Cheon, Sung Yun Park, Juhyun Song, Ju-Hee Lee, Valero, Jorge, Mongin, Alexander A., and Giampà, Carmela
- Subjects
MICROGLIA ,CENTRAL nervous system ,MACROPHAGES ,HOMEOSTASIS ,NEUROLOGICAL disorders - Abstract
Microglia are the resident macrophages in the central nervous system (CNS) and play essential roles in neuronal homeostasis and neuroinflammatory pathologies. Recently, microglia have been shown to contribute decisively to neuropathologic processes after ischemic stroke. Furthermore, natural compounds have been reported to attenuate inflammation and pathologies associated with neuroinflammation. Tryptanthrin (indolo[2,1-b]quinazoline-6,12-dione) is a phytoalkaloid with known anti-inflammatory effects in cells. In present study, the authors confirmed middle cerebral artery occlusion (MCAO) injury triggers the activation of microglia in brain tissue, and investigated whether tryptanthrin influences the function of mouse murine BV2 microglia under LPS-induced inflammatory conditions in vitro. It was found tryptanthrin protected BV2 microglia cells against LPS-induced inflammation and inhibited the induction of M1 phenotype microglia under inflammatory conditions. In addition, tryptanthrin reduced the production of pro-inflammatory cytokines in BV2 microglia cells via nuclear factor erythroid 2-related factor 2 (Nrf2)/heme oxygenase 1 (HO-1) signaling and NF-ΚB signaling. The authors suggest that tryptanthrin might alleviate the progress of neuropathologies by controlling microglial functions under neuroinflammatory conditions. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
11. PARP-1 Inhibition Is Neuroprotective in the R6/2 Mouse Model of Huntington’s Disease.
- Author
-
Cardinale, Antonella, Paldino, Emanuela, Giampà, Carmela, Bernardi, Giorgio, and Fusco, Francesca R.
- Subjects
NEUROPROTECTIVE agents ,LABORATORY mice ,HUNTINGTON disease ,POLYMERASES ,DNA repair ,APOPTOSIS - Abstract
Poly (ADP-ribose) polymerase 1 (PARP-1) is a nuclear enzyme that is involved in physiological processes as DNA repair, genomic stability, and apoptosis. Moreover, published studies demonstrated that PARP-1 mediates necrotic cell death in response to excessive DNA damage under certain pathological conditions. In Huntington’s disease brains, PARP immunoreactivity was described in neurons and in glial cells, thereby suggesting the involvement of apoptosis in HD. In this study, we sought to determine if the PARP-1 inhibitor exerts a neuroprotective effect in R6/2 mutant mice, which recapitulates, in many aspects, human HD. Transgenic mice were treated with the PARP-1 inhibitor INO-1001 mg/Kg daily starting from 4 weeks of age. After transcardial perfusion, histological and immunohistochemical studies were performed. We found that INO 1001-treated R6/2 mice survived longer and displayed less severe signs of neurological dysfunction than the vehicle treated ones. Primary outcome measures such as striatal atrophy, morphology of striatal neurons, neuronal intranuclear inclusions and microglial reaction confirmed a neuroprotective effect of the compound. INO-1001 was effective in significantly increasing activated CREB and BDNF in the striatal spiny neurons, which might account for the beneficial effects observed in this model. Our findings show that PARP-1 inhibition could be considered as a valid therapeutic approach for HD. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
12. Systemic Delivery of Recombinant Brain Derived Neurotrophic Factor (BDNF) in the R6/2 Mouse Model of Huntington’s Disease
- Author
-
Giampà, Carmela, Montagna, Elena, Dato, Clemente, Melone, Mariarosa A. B., Bernardi, Giorgio, and Fusco, Francesca Romana
- Subjects
- *
HUNTINGTON disease , *RECOMBINANT proteins , *BRAIN-derived neurotrophic factor , *HUNTINGTIN protein , *GENETIC engineering , *MESSENGER RNA , *LABORATORY mice - Abstract
Loss of huntingtin-mediated BDNF gene transcription has been shown to occur in HD and thus contribute to the degeneration of the striatum. Several studies have indicated that an increase in BDNF levels is associated with neuroprotection and amelioration of neurological signs in animal models of HD. In a recent study, an increase in BDNF mRNA and protein levels was recorded in mice administered recombinant BDNF peripherally. Chronic, indwelling osmotic mini-pumps containing either recombinant BDNF or saline were surgically placed in R6/2 or wild-type mice from 4 weeks of age until euthanasia. Neurological evaluation (paw clasping, rotarod performance, locomotor activity in an open field) was performed. After transcardial perfusion, histological and immunohistochemical studies were performed. We found that BDNF- treated R6/2 mice survived longer and displayed less severe signs of neurological dysfunction than the vehicle treated ones. Primary outcome measures such as brain volume, striatal atrophy, size and morphology of striatal neurons, neuronal intranuclear inclusions and microglial reaction confirmed a neuroprotective effect of the compound. BDNF was effective in increasing significantly the levels of activated CREB and of BDNF the striatal spiny neurons. Moreover, systemically administered BDNF increased the synthesis of BDNF as demonstrated by RT-PCR, and this might account for the beneficial effects observed in this model. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
13. Rebalance of Striatal NMDA/AMPA Receptor Ratio Underlies the Reduced Emergence of Dyskinesia During D2-Like Dopamine Agonist Treatment in Experimental Parkinson's Disease.
- Author
-
Bagetta, Vincenza, Sgobio, Carmelo, Pendolino, Valentina, Papa, Giulia Del, Tozzi, Alessandro, Ghiglieri, Veronica, Giampà, Carmela, Zianni, Elisa, Gardoni, Fabrizio, Calabresi, Paolo, and Picconi, Barbara
- Subjects
PARKINSON'S disease treatment ,METHYL aspartate receptors ,MOVEMENT disorders ,DOPAMINE ,TREATMENT effectiveness ,PREVENTIVE medicine - Abstract
Dopamine replacement with levodopa (Ɩ-DOPA) represents the mainstay of Parkinson's disease (PD) therapy. Nevertheless, this well established therapeutic intervention loses efficacy with the progression of the disease and patients develop invalidating side effects, known in their complex as Ɩ-DOPA-induced dyskinesia (LID). Unfortunately, existing therapies fail to prevent LID and very few drugs are available to lessen its severity, thus representing a major clinical problem in PD treatment. D2-like receptor (D2R) agonists are a powerful clinical option as an alternative to Ɩ-DOPA, especially in the early stages of the disease, being associated to a reduced risk of dyskinesia development. D2R agonists also find considerable application in the advanced stages of PD, in conjunction with Ɩ-DOPA, which is used in this context at lower dosages, to delay the appearance and the extent of the motor complications. In advanced stages of PD, D2R agonists are often effective in delaying the appearance and the extent of motor complications. Despite the great attention paid to the family of D2R agonists, the main reasons underlying the reduced risk of dyskinesia have not yet been fully characterized. Here we show that the striatal NMDA/AMPA receptor ratio and the AMPA receptor subunit composition are altered in experimental parkinsonism in rats. Surprisingly, while Ɩ-DOPA fails to restore these critical synaptic alterations, chronic treatment with pramipexole is associated not only with a reduced risk of dyskinesia development but is also able to rebalance, in a dose-dependent fashion, the physiological synaptic parameters, thus providing new insights into the mechanisms of dyskinesia. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
14. Immunohistochemical localization of receptor for advanced glycation end (RAGE) products in the R6/2 mouse model of Huntington's disease
- Author
-
Anzilotti, Serenella, Giampà, Carmela, Laurenti, Daunia, Perrone, Lorena, Bernardi, Giorgio, Melone, Mariarosa A.B., and Fusco, Francesca R.
- Subjects
- *
IMMUNOHISTOCHEMISTRY , *HUNTINGTON disease , *LIGANDS (Biochemistry) , *NEURODEGENERATION , *IMMUNOGLOBULINS , *LABORATORY mice - Abstract
Abstract: The receptor for advanced glycation end (RAGE) products is a multi-ligand receptor that belongs to the immunoglobulin superfamily of cell surface receptors, whose ligands are known to be upregulated in neuropathological conditions. RAGE upregulation has been described in neurodegenerative diseases, such as Alzheimer''s disease, Creutzfeldt–Jakob''s disease and Huntington''s disease (HD). To analyze in detail the implication of RAGE in HD, we studied the immunohistochemical distribution of RAGE in the striatum of the R6/2 mouse model of HD, with particular attention to the neuronal subpopulations and their relative vulnerability to HD neurodegeneration. We show that RAGE immunoreactivity is evenly distributed to the cytoplasm of neurons in the wild type mouse, while it is finely granular in the cytoplasm of striatal neurons of R6/2 mouse. RAGE is distributed in 98% of spiny projection neurons, both in the normal mouse and in the R6/2. RAGE co-localizes with all of the striatal interneuron subsets both in the wild-type and in the R6/2 mouse. However, the intensity of RAGE immunoreactivity is significantly higher in the spiny neurons and in the PARV neurons of R6/2 mouse, whereas it is comparable between R6/2 and wild-type in the cholinergic and somatostatinergic interneurons. These data support the concept that RAGE is upregulated in the neurodegenerative process of HD, and suggests that its activation is related to the individual vulnerability of the striatal neuronal subtype. [Copyright &y& Elsevier]
- Published
- 2012
- Full Text
- View/download PDF
15. Distinct Levels of Dopamine Denervation Differentially Alter Striatal Synaptic Plasticity and NMDA Receptor Subunit Composition.
- Author
-
Paillé, Vincent, Picconi, Barbara, Bagetta, Vincenza, Ghiglieri, Veronica, Sgobio, Carmelo, Di Filippo, Massimiiano, Viscomi, Maria T., Giampà, Carmela, Fusco, Francesca R., Gardoni, Fabrizio, Bernardi, Giorgio, Greengard, Paul, Di Luca, Monica, and Calabresi, Paolo
- Subjects
DOPAMINE ,DENERVATION ,NEUROPLASTICITY ,GLUTAMIC acid ,ANIMAL models in research ,PARKINSON'S disease ,DRUG synergism - Abstract
A correct interplay between dopamine (DA) and glutamate is essential for corticostriatal synaptic plasticity and motor activity. In an experimental model of Parkinson's disease (PD) obtained in rats, the complete depletion of striatal DA, mimicking advanced stages of the disease, results in the loss of both forms of striatal plasticity: long-term potentiation (LIP) and long-term depression (LID). However, early PD stages are characterized by an incomplete reduction in striatal DA levels. The mechanism by which this incomplete reduction in DA level affects striatal synaptic plasticity and glutamatergic synapses is unknown. Here we present a model of early PD in which a partial denervation, causing mild motor deficits, selectively affects NMDA-dependent LIP but not LID and dramatically alters NMDA receptor composition in the postsynaptic density. Our findings show that DA decrease influences corticostriatal synaptic plasticity depending on the level of depletion. The use of the TAI2A cell-permeable peptide, as an innovative therapeutic strategy in early PD, rescues physiological NMDA receptor composition, synaptic plasticity, and motor behavior. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
16. Inhibition of the Striatal Specific Phosphodiesterase PDE10A Ameliorates Striatal and Cortical Pathology in R6/2 Mouse Model of Huntington's Disease.
- Author
-
Giampà, Carmela, Laurenti, Daunia, Anzilotti, Serenella, Bernardi, Giorgio, Menniti, Frank S., and Fusco, Francesca Romana
- Subjects
- *
PHOSPHODIESTERASES , *CLINICAL pathology , *HUNTINGTON disease , *DIAGNOSIS of neurological disorders , *DISEASE progression , *LABORATORY mice , *GENETIC mutation , *CYCLIC adenylic acid , *BIOCHEMICAL genetics - Abstract
Background: Huntington's disease is a devastating neurodegenerative condition for which there is no therapy to slow disease progression. The particular vulnerability of striatal medium spiny neurons to Huntington's pathology is hypothesized to result from transcriptional dysregulation within the cAMP and CREB signaling cascades in these neurons. To test this hypothesis, and a potential therapeutic approach, we investigated whether inhibition of the striatal-specific cyclic nucleotide phosphodiesterase PDE10A would alleviate neurological deficits and brain pathology in a highly utilized model system, the R6/2 mouse. Methodology/Principal Findings: R6/2 mice were treated with the highly selective PDE10A inhibitor TP-10 from 4 weeks of age until euthanasia. TP-10 treatment significantly reduced and delayed the development of the hind paw clasping response during tail suspension, deficits in rotarod performance, and decrease in locomotor activity in an open field. Treatment prolonged time to loss of righting reflex. These effects of PDE10A inhibition on neurological function were reflected in a significant amelioration in brain pathology, including reduction in striatal and cortical cell loss, the formation of striatal neuronal intranuclear inclusions, and the degree of microglial activation that occurs in response to the mutant huntingtin-induced brain damage. Striatal and cortical levels of phosphorylated CREB and BDNF were significantly elevated. Conclusions/Significance: Our findings provide experimental support for targeting the cAMP and CREB signaling pathways and more broadly transcriptional dysregulation as a therapeutic approach to Huntington's disease. It is noteworthy that PDE10A inhibition in the R6/2 mice reduces striatal pathology, consistent with the localization of the enzyme in medium spiny neurons, and also cortical pathology and the formation of neuronal nuclear inclusions. These latter findings suggest that striatal pathology may be a primary driver of these secondary pathological events. More significantly, our studies point directly to an accessible new therapeutic approach to slow Huntington's disease progression, namely, PDE10A inhibition. There is considerable activity throughout the pharmaceutical industry to develop PDE10A inhibitors for the treatment of basal ganglia disorders. The present results strongly support the investigation of PDE10A inhibitors as a much needed new treatment approach to Huntington's disease. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
17. TrkB/BDNF-Dependent Striatal Plasticity and Behavior in a Genetic Model of Epilepsy: Modulation by Valproic Acid.
- Author
-
Ghiglieri, Veronica, Sgobio, Carmelo, Patassini, Stefano, Bagetta, Vincenza, Fejtova, Anna, Giampà, Carmela, Marinucci, Silvia, Heyden, Alexandra, Gundelfinger, Eckart D., Fusco, Francesca R., Calabresi, Paolo, and Picconi, Barbara
- Subjects
NEUROPLASTICITY ,EPILEPSY ,VALPROIC acid ,GENETIC mutation ,ACETIC acid - Abstract
In mice lacking the central domain of the presynaptic scaffold Bassoon the occurrence of repeated cortical seizures induces cell-type-specific plasticity changes resulting in a general enhancement of the feedforward inhibition within the striatal microcircuit. Early antiepileptic treatment with valproic acid (VPA) reduces epileptic attacks, inhibits the emergence of pathological form of plasticity in fast-spiking (FS) interneurons and restores physiological striatal synaptic plasticity in medium spiny (MS) neurons. Brain-derived neurotrophic factor (BDNF) is a key factor for the induction and maintenance of synaptic plasticity and it is also implicated in the mechanisms underlying epilepsy-induced adaptive changes. In this study, we explore the possibility that the TrkB/BDNF system is involved in the striatal modifications associated with the Bassoon gene (Bsn) mutation. In epileptic mice abnormal striatum-dependent learning was paralleled by higher TrkB levels and an altered distribution of BDNF. Accordingly, subchronic intrastriatal administration of k252a, an inhibitor of TrkB receptor tyrosine kinase activity, reversed behavioral alterations in Bsn mutant mice. In addition, in vitro manipulations of the TrkB/BDNF complex by k252a, prevented the emergence of pathological plasticity in FS interneurons. Chronic treatment with VPA, by reducing seizures, was able to rebalance TrkB to control levels favoring a physiological redistribution of BDNF between MS neurons and FS interneurons with a concomitant recovery of striatal plasticity. Our results provide the first indication that BDNF is involved in determining the striatal alterations occurring in the early-onset epileptic syndrome associated with the absence of presynaptic protein Bassoon. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
18. Phosphodiesterase 10 inhibition reduces striatal excitotoxicity in the quinolinic acid model of Huntington's disease
- Author
-
Giampà, Carmela, Patassini, Stefano, Borreca, Antonella, Laurenti, Daunia, Marullo, Fabrizia, Bernardi, Giorgio, Menniti, Frank S., and Fusco, Francesca R.
- Subjects
- *
HUNTINGTON disease , *IMMUNOHISTOCHEMISTRY , *NERVOUS system , *CARRIER proteins - Abstract
Abstract: Decreased activity of cAMP responsive element-binding protein (CREB) is thought to contribute to the death of striatal medium spiny neurons in Huntington''s disease (HD). Therefore, therapies that increase levels of activated CREB, may be effective in fighting neurodegeneration in HD. In this study, we sought to determine whether the phosphodiesterase type 10 (PDE10A) inhibitor TP10 exerts a neuroprotective effect in an excitotoxic model of HD. Rats were surgically administered with quinolinic acid into striatum and subsequently treated with TP10 daily for two or eight weeks. After 2 weeks of TP10 treatment, striatal lesion size was 52% smaller and the surviving cell number was several times higher than in the vehicle-treated group. These beneficial effects of TP10 were maintained through 8 weeks. TP10 treatment also increased significantly the levels of activated CREB in the striatal spiny neurons, which is hypothesized to be a contributing mechanism for the neuroprotective effect. Our findings suggest PDE10A inhibition as a novel neuroprotective approach to the treatment of HD and confirm the importance of phosphodiesterase inhibition in fighting the disease. [Copyright &y& Elsevier]
- Published
- 2009
- Full Text
- View/download PDF
19. Effects of simvastatin on neuroprotection and modulation of Bcl-2 and BAX in the rat quinolinic acid model of Huntington's disease
- Author
-
Patassini, Stefano, Giampà, Carmela, Martorana, Alessandro, Bernardi, Giorgio, and Fusco, Francesca R.
- Subjects
- *
ANTILIPEMIC agents , *NEUROPROTECTIVE agents , *QUINOLINIC acid , *HUNTINGTON disease , *LABORATORY rats , *ANIMAL models in research - Abstract
Abstract: A possible neuroprotective role has been recently suggested for 3H3MGCoA reductase inhibitors. Here, we sought to determine whether simvastatin exerts a neuroprotective effect in our rat model of HD. Rats were surgically administered quinolinic acid and treated with simvastatin 1mg/kg intraperitoneally (i.p.) once daily up to 2 or 8 weeks. Two more groups of animals received a pretreatment with 1mg/kg simvastatin i.p. for 2 weeks before the QA lesion and then were treated with simvastatin for the following 2 weeks or 8 weeks, respectively. In the simvastatin treated groups (both pretreated and non-pretreated), striatal lesion size was about 36% smaller while neuronal counts where higher than in the vehicle treated ones at 2 weeks. The neuroprotective effects of simvastatin was still evident at 8 weeks post lesion, where the non-pretreated group had a 8% smaller lesion size than the saline group, and the pretreated group had an 11% smaller lesion size than the saline group. Simvastatin also induced immunoreactivity for Bcl-2, an anti-apoptotic factor, on one hand, and down-regulated immunoreactivity for Bax, a proapoptotic factor. Bcl-2/Bax modulation can account, at least partly, for the beneficial effect of simvastatin in our rodent model of striatal degeneration. Our findings show that statins could be explored as possible neuroprotective agents for neurodegenerative disorders such as HD. [Copyright &y& Elsevier]
- Published
- 2008
- Full Text
- View/download PDF
20. Beneficial effects of rolipram in the R6/2 mouse model of Huntington's disease
- Author
-
DeMarch, Zena, Giampà, Carmela, Patassini, Stefano, Bernardi, Giorgio, and Fusco, Francesca Romana
- Subjects
- *
HUNTINGTON disease , *RODENTS , *TRANSGENIC mice , *TRYPTOPHAN - Abstract
Abstract: We have previously showed that rolipram, a phosphodiesterase type IV inhibitor, displays a neuroprotective effect in a rat quinolinic acid model of HD [DeMarch Z., Giampa C., Patassini S., Martorana A., Bernardi G. and Fusco F.R., (2007) Beneficial effects of rolipram in a quinolinic acid model of striatal excitotoxicity. Neurobiol. Dis. 25:266–273.]. In this study, we sought to determine if rolipram exerts a neuroprotective effect in R6/2 mutant mice, which recapitulates, in many aspects, human HD [Mangiarini L., Sathasivam K., Seller M., Cozens B., Harper A., Hetherington C., Lawton M., Trottier Y., Lehrach H., Davies S.W. and Bates G.P. (1996) Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell. 87:493–506]. Transgenic mice were treated with rolipram 1.5 mg/kg daily starting from 4 weeks of age. After transcardial perfusion, histological and immunohistochemical studies were performed. We found that rolipram-treated R6/2 mice survived longer and displayed less severe signs of neurological dysfunction than the vehicle treated ones. Primary outcome measures such as brain volume, striatal atrophy, size and morphology of striatal neurons, neuronal intranuclear inclusions and microglial reaction confirmed a neuroprotective effect of the compound. Rolipram was effective in increasing significantly the levels of activated CREB and of BDNF the striatal spiny neurons, which might account for the beneficial effects observed in this model. Our findings show that rolipram could be considered as a valid therapeutic approach for HD. [Copyright &y& Elsevier]
- Published
- 2008
- Full Text
- View/download PDF
21. Immunohistochemical localization of TRPC6 in the rat substantia nigra
- Author
-
Giampà, Carmela, DeMarch, Zena, Patassini, Stefano, Bernardi, Giorgio, and Fusco, Francesca R.
- Subjects
- *
IMMUNOHISTOCHEMISTRY , *TRP channels , *ANIMAL models in research , *RATS - Abstract
Abstract: Transient receptor potential channels (TRPC) are plasma membrane, nonselective cationic channels and have been proposed as candidates involved in the regulation of cellular Ca2+ influx [D.E. Clapham, L.W. Runnels, C., Strubing, The TRP ion channel family, Nat. Rev. Neurosci. 2 (2001) 387–396; A. Martorana, C. Giampa, Z. DeMarch, M.T. Viscomi, S. Patassini, G. Sancesario, G. Bernardi, F.R. Fusco, Distribution of TRPC1 receptors in dendrites of rat substantia nigra: a confocal and electron microscopy study, Eur. J. Neurosci. 24 (2006) 732–738]. Studies on regional localization patterns of TRPCs are necessary to provide helpful guidelines for correlating current types with particular channels. In this study, we examined the distribution of one particular member of TRPC superfamily, namely, TRPC6, in the substantia nigra of normal rat brain. Single and double label immunohistochemistry were employed to perform both light and confocal microscopy observations. Our single label studies showed that, in the substantia nigra, TRPC6 labeled the perikarya with a diffuse and intense immunoreaction product distributed throughout cell cytoplasm whereas only a light immunostaining was observed in the cell nuclei. No labeling of axon or terminals was observed, although TRPC6 was evenly distributed in the neuropil. Our dual label studies showed a TRPC6 immunoreactivity pattern that was localized into the proximal dendrites and axon hillock of the large dopaminergic neurons identified by TH immunoreaction. Furthermore, our double label immunofluorescence study for TRPC6 and mGluR1 showed a complete co-localization of the two markers in the substantia nigra. Moreover, TRPC6 did not co-localize with synaptophysin. Thus, our study shows the postsynaptic localization of TRPC6 and its association with mGluR1 in the midbrain dopamine neurons. [Copyright &y& Elsevier]
- Published
- 2007
- Full Text
- View/download PDF
22. Beneficial effects of rolipram in a quinolinic acid model of striatal excitotoxicity
- Author
-
DeMarch, Zena, Giampà, Carmela, Patassini, Stefano, Martorana, Alessandro, Bernardi, Giorgio, and Fusco, Francesca Romana
- Subjects
- *
LABORATORY rats , *HUNTINGTON disease , *CARRIER proteins , *DRUGS - Abstract
Abstract: Activity of c-AMP responsive element-binding protein (CREB) is decreased in Huntington’s disease (HD). Such decrease was also described by our group in the quinolinic acid lesion model of striatal excitotoxicity. The phosphodiesterase type IV inhibitor rolipram increases CREB phosphorylation. Such drug has a protective effect in global ischaemia and embolism in rats. In this study, we sought to determine whether rolipram displays a neuroprotective effect in our rat model of HD. Animals were surgically administered QA and subsequently treated with rolipram daily up to 2 and 8 weeks respectively. After these time points, rats were sacrificed and immunohistochemical studies were performed in the striata. In the rolipram-treated animals, striatal lesion size was about 62% smaller that in the vehicle-treated ones at 2 weeks time point. Moreover, the surviving cell number was several times higher in the rolipram-treated animals than in the vehicle group at both time points. Rolipram also showed to be effective in increasing significantly the levels of activated CREB in the striatal spiny neurons, which accounts mostly for its beneficial effect in our rodent model of excitotoxicity. Our findings show that rolipram could be considered as a valid therapeutic approach for HD. [Copyright &y& Elsevier]
- Published
- 2007
- Full Text
- View/download PDF
23. Cellular localization of TRPC5 in the substantia nigra of rat
- Author
-
De March, Zena, Giampà, Carmela, Patassini, Stefano, Bernardi, Giorgio, and Fusco, Francesca R.
- Subjects
- *
IMMUNOHISTOCHEMISTRY , *NERVOUS system , *CONFOCAL microscopy , *NEUROTRANSMITTERS - Abstract
Abstract: Transient receptor potential channels (TRPC) are plasma membrane, non-selective cationic channels and have been proposed as candidates involved in the regulation of cellular Ca2+ influx. TRPC are involved in metabotropic glutamate receptor (mGluR)-mediated excitatory post-synaptic currents (EPSCs) in the dopaminergic neurons of the substantia nigra. We previously observed several subtypes of TRPC to be expressed at an mRNA level in the substantia nigra dopamine neurons. In particular, TRPC1 and TRPC5 are most frequently expressed in the substantia nigra. Our recent immunohistochemical findings showed that TRPC1 are mainly distributed in the dendrites of dopamine neurons. In the present study we have investigated, by means of immunohistochemistry and dual label immunofluorescence, the anatomical distribution of TRPC5 in the substantia nigra, and we have shown their preferential localization into the neuronal nuclei. Our findings suggest a role of TRPs in the calcium signaling system of the nucleus, although its physiological meaning needs further investigations. [Copyright &y& Elsevier]
- Published
- 2006
- Full Text
- View/download PDF
24. Correction: Systemic Delivery of Recombinant Brain Derived Neurotrophic Factor (BDNF) in the R6/2 Mouse Model of Huntington's Disease.
- Author
-
Giampà, Carmela, Montagna, Elena, Dato, Clemente, Melone, Mariarosa A. B., Bernardi, Giorgio, and Fusco, Francesca Romana
- Subjects
- *
BRAIN-derived neurotrophic factor , *HUNTINGTON disease , *LABORATORY mice - Published
- 2016
- Full Text
- View/download PDF
25. A Case of PANDAS Treated With Tetrabenazine and Tonsillectomy.
- Author
-
Fusco, Francesca Romana, Pompa, Alessandra, Bernardi, Giorgio, Ottaviani, Fabrizio, Giampà, Carmela, Laurenti, Daunia, Morello, Maria, Bernardini, Sergio, Nuccetelli, Marzia, Sabatini, Umberto, and Paolucci, Stefano
- Subjects
AUTOIMMUNE diseases ,STREPTOCOCCAL diseases ,RARE diseases ,CHOREA ,JUVENILE diseases ,TONSILLECTOMY - Abstract
PANDAS (pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections) is a rare clinical syndrome characterized by the presence of tics, Tourette syndrome, obsessive-compulsive disorder, or chorea in the context of an immediately precedent streptococcal infection. In this report, we describe the case of an 11-year-old boy who developed PANDAS with severe choreic movements. The criteria for PANDAS diagnosis were met. Moreover, serum antibrain antibodies were present. The patient was initially treated with tetrabenazine 12.5 mg twice daily with remission of the neurological symptoms. Subsequently, the patient underwent tonsillectomy and has been asymptomatic since, with antistreptolysin O titer levels in range. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
26. Erratum: Persistent activation of microglia and NADPH oxidase drive hippocampal dysfunction in experimental multiple sclerosis.
- Author
-
Di Filippo, Massimiliano, de Iure, Antonio, Giampà, Carmela, Chiasserini, Davide, Tozzi, Alessandro, Orvietani, Pier Luigi, Ghiglieri, Veronica, Tantucci, Michela, Durante, Valentina, Quiroga-Varela, Ana, Mancini, Andrea, Costa, Cinzia, Sarchielli, Paola, Fusco, Francesca Romana, and Calabresi, Paolo
- Published
- 2016
- Full Text
- View/download PDF
27. Persistent activation of microglia and NADPH drive hippocampal dysfunction in experimental multiple sclerosis.
- Author
-
Di Filippo, Massimiliano, de Iure, Antonio, Giampà, Carmela, Chiasserini, Davide, Tozzi, Alessandro, Orvietani, Pier Luigi, Ghiglieri, Veronica, Tantucci, Michela, Durante, Valentina, Quiroga-Varela, Ana, Mancini, Andrea, Costa, Cinzia, Sarchielli, Paola, Fusco, Francesca Romana, and Calabresi, Paolo
- Published
- 2016
- Full Text
- View/download PDF
28. Rhes influences striatal cAMP/PKA-dependent signaling and synaptic plasticity in a gender-sensitive fashion.
- Author
-
Ghiglieri, Veronica, Usiello, Alessandro, Napolitano, Francesco, Errico, Francesco, Pelosi, Barbara, Migliarini, Sara, Maddaloni, Giacomo, Schepisi, Chiara, Nisticò, Robert, Di Maio, Anna, Pendolino, Valentina, Mancini, Maria, Giampà, Carmela, Picconi, Barbara, Sciamanna, Giuseppe, Vitucci, Daniela, and Pasqualetti, Massimo
- Subjects
NEUROPLASTICITY ,BRAIN ,ESTROGEN ,KNOCKOUT mice ,THYROID hormones ,GENETIC code ,BEHAVIOR analysts ,BEHAVIORAL assessment - Abstract
Mechanisms of gender-specific synaptic plasticity in the striatum, a brain region that controls motor, cognitive and psychiatric functions, remain unclear. Here we report that Rhes, a GTPase enriched in medium spiny neurons (MSNs) of striatum, alters the striatal cAMP/PKA signaling cascade in a gender-specific manner. While Rhes knockout (KO) male mice, compared to wild-type (WT) mice, had a significant basal increase of cAMP/PKA signaling pathway, the Rhes KO females exhibited a much stronger response of this pathway, selectively under the conditions of dopamine/adenosine-related drug challenge. Corticostriatal LTP defects are exclusively found in A2AR/D2R-expressing MSNs of KO females, compared to KO males, an effect that is abolished by PKA inhibitors but not by the removal of circulating estrogens. This suggests that the synaptic alterations found in KO females could be triggered by an aberrant A2AR/cAMP/PKA activity, but not due to estrogen-mediated effect. Consistent with increased cAMP signaling, D1R-mediated motor stimulation, haloperidol-induced catalepsy and caffeine-evoked hyper-activity are robustly enhanced in Rhes KO females compared to mutant males. Thus Rhes, a thyroid hormone-target gene, plays a relevant role in gender-specific synaptic and behavioral responses. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
29. Phosphodiesterase 10A (PDE10A) localization in the R6/2 mouse model of Huntington's disease
- Author
-
Leuti, Alessandro, Laurenti, Daunia, Giampà, Carmela, Montagna, Elena, Dato, Clemente, Anzilotti, Serenella, Melone, Mariarosa A.B., Bernardi, Giorgio, and Fusco, Francesca R.
- Subjects
- *
PHOSPHODIESTERASES , *GENETIC mutation , *HUNTINGTON disease , *HUNTINGTIN protein , *TRANSCRIPTION factors , *CREB protein , *IMMUNOHISTOCHEMISTRY , *LABORATORY mice - Abstract
Abstract: In Huntington''s disease (HD) mutant huntingtin protein impairs the function of several transcription factors, in particular the cAMP response element-binding protein (CREB). CREB activation can be increased by targeting phosphodiesterases such as phospohodiesterase 4 (PDE4) and phosphodiesterase 10A (PDE10A). Indeed, both PDE4 inhibition (DeMarch et al., 2008) and PDE10A inhibition (Giampà et al., 2010) proved beneficial in the R6/2 mouse model of HD. However, Hebb et al. (2004) reported PDE10A decline in R6/2 mice. These findings raise the issue of how PDE10A inhibition is beneficial in HD if such enzyme is lost. R6/2 mice and their wild type littermates were treated with the PDE10A inhibitor TP10 (a gift from Pfizer) or saline, sacrificed at 5, 9, and 13weeks of age, and single and double label immunohistochemistry and western blotting were performed. PDE10A increased dramatically in the spiny neurons of R6/2 compared to the wild type mice. Conversely, in the striatal cholinergic interneurons, PDE10A was lower and it did not change significantly with disease progression. In the other subsets of striatal interneurons (namely, parvalbuminergic, somatostatinergic, and calretininergic interneurons) PDE10A immunoreactivity was higher in the R6/2 compared to the wild-type mice. In the TP10 treated R6/2, PDE10A levels were lower than in the saline treated mice in the medium spiny neurons, whereas they were higher in all subsets of striatal interneurons except for the cholinergic ones. However, in the whole striatum densitometry studies, PDE10A immunoreactivity was lower in the R6/2 compared to the wild-type mice. Our study demonstrates that PDE10A is increased in the spiny neurons of R6/2 mice striatum. Thus, the accumulation of PDE10A in the striatal projection neurons, by hydrolyzing greater amounts of cyclic nucleotides, is likely to contribute to cell damage in HD. Consequently, the beneficial effect of TP10 in HD models (Giampà et al., 2009, 2010) is explained by the efficiency of such compound in counteracting this phenomenon and therefore increasing the availability of cyclic nucleotides. [Copyright &y& Elsevier]
- Published
- 2013
- Full Text
- View/download PDF
30. Changes in the expression of extracellular regulated kinase (ERK 1/2) in the R6/2 mouse model of Huntington's disease after phosphodiesterase IV inhibition
- Author
-
Fusco, Francesca R., Anzilotti, Serenella, Giampà, Carmela, Dato, Clemente, Laurenti, Daunia, Leuti, Alessandro, Colucci D'Amato, Luca, Perrone, Lorena, Bernardi, Giorgio, and Melone, Mariarosa A.B.
- Subjects
- *
ANIMAL models in research , *HUNTINGTON disease , *PHOSPHODIESTERASE inhibitors , *MITOGEN-activated protein kinases , *NEURODEGENERATION , *PATHOLOGICAL physiology , *PHOSPHORYLATION , *LABORATORY mice - Abstract
Abstract: The mitogen-activated protein kinases (MAPKs) superfamily comprises three major signaling pathways: the extracellular signal-regulated protein kinases (ERKs), the c-Jun N-terminal kinases or stress-activated protein kinases (JNKs/SAPKs) and the p38 family of kinases. ERK 1/2 signaling has been implicated in a number of neurodegenerative disorders, including Huntington''s disease (HD). Phosphorylation patterns of ERK 1/2 and JNK are altered in cell models of HD. In this study, we aimed at studying the correlations between ERK 1/2 and the neuronal vulnerability to HD degeneration in the R6/2 transgenic mouse model of HD. Single and double-label immunofluorescence for phospho-ERK (pERK, the activated form of ERK) and for each of the striatal neuronal markers were employed on perfusion-fixed brain sections from R6/2 and wild-type mice. Moreover, Phosphodiesterase 4 inhibition through rolipram was used to study the effects on pERK expression in the different types of striatal neurons. We completed our study with western blot analysis. Our study shows that pERK levels increase with age in the medium spiny striatal neurons and in the parvalbumin interneurons, and that rolipram counteracts such increase in pERK. Conversely, cholinergic and somatostatinergic interneurons of the striatum contain higher levels of pERK in the R6/2 mice compared to the controls. Rolipram induces an increase in pERK expression in these interneurons. Thus, our study confirms and extends the concept that the expression of phosphorylated ERK 1/2 is related to neuronal vulnerability and is implicated in the pathophysiology of cell death in HD. [Copyright &y& Elsevier]
- Published
- 2012
- Full Text
- View/download PDF
31. Cellular localization of TRPC3 channel in rat brain: preferential distribution to oligodendrocytes
- Author
-
Fusco, Francesca R., Martorana, Alessandro, Giampà, Carmela, March, Zena De, Vacca, Fabrizio, Tozzi, Alessandro, Longone, Patrizia, Piccirilli, Silvia, Paolucci, Stefano, Sancesario, Giuseppe, Mercuri, Nicola B., and Bernardi, Giorgio
- Subjects
- *
DENDRITIC cells , *CONFOCAL microscopy , *ELECTRON microscopy , *ANTIGEN presenting cells - Abstract
In the present work we describe the cellular localization of TRPC3 in non-excitable cells as compared to the neurons in normal rat brain. We performed a double labeling study for TRPC3 and one of the following cell-specific markers: mouse anti-glial fibrillary acidic protein (GFAP) for astrocytes; mouse anti-RIP for oligodendrocytes, or mouse anti-OX42 for microglia, or mouse anti-NeUN for neuronal nuclei or mouse anti-tyrosine hydroxylase (TH) for detection of dopaminergic neurons of the substantia nigra. Our double label immunofluorescence study showed that that TRPC3 is mainly localized in oligodendrocytes. These result were confirmed by the electron microscopy study, which showed TRPC3 immunoreactivity in oligodendrocytes. Consistent with the evidence that calcium homeostasis is important to oligodendrocytes for development, myelination, and demyelination [Microsc. Res. Tech. 52 (2001) 672], we can speculate that the distribution of TRPC3 in oligodendrocytes plays a role in myelination and or demyelination processes. [Copyright &y& Elsevier]
- Published
- 2004
- Full Text
- View/download PDF
32. Microglial activation and the nitric oxide/cGMP/PKG pathway underlie enhanced neuronal vulnerability to mitochondrial dysfunction in experimental multiple sclerosis.
- Author
-
Mancini, Andrea, Tantucci, Michela, Mazzocchetti, Petra, de Iure, Antonio, Durante, Valentina, Macchioni, Lara, Giampà, Carmela, Alvino, Alessandra, Gaetani, Lorenzo, Costa, Cinzia, Tozzi, Alessandro, Calabresi, Paolo, and Di Filippo, Massimiliano
- Subjects
- *
MULTIPLE sclerosis , *MICROGLIA , *CGMP-dependent protein kinase , *NITRIC oxide , *MITOCHONDRIAL pathology , *NEURODEGENERATION - Abstract
During multiple sclerosis (MS), a close link has been demonstrated to occur between inflammation and neuro-axonal degeneration, leading to the hypothesis that immune mechanisms may promote neurodegeneration, leading to irreversible disease progression. Energy deficits and inflammation-driven mitochondrial dysfunction seem to be involved in this process. In this work we investigated, by the use of striatal electrophysiological field-potential recordings, if the inflammatory process associated with experimental autoimmune encephalomyelitis (EAE) is able to influence neuronal vulnerability to the blockade of mitochondrial complex IV, a crucial component for mitochondrial activity responsible of about 90% of total cellular oxygen consumption. We showed that during the acute relapsing phase of EAE, neuronal susceptibility to mitochondrial complex IV inhibition is markedly enhanced. This detrimental effect was counteracted by the pharmacological inhibition of microglia, of nitric oxide (NO) synthesis and its intracellular pathway (involving soluble guanylyl cyclase , sGC, and protein kinase G , PKG). The obtained results suggest that mitochondrial complex IV exerts an important role in maintaining neuronal energetic homeostasis during EAE. The pathological processes associated with experimental MS, and in particular the activation of microglia and of the NO pathway, lead to an increased neuronal vulnerability to mitochondrial complex IV inhibition, representing promising pharmacological targets. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
33. Alpha-Synuclein Produces Early Behavioral Alterations via Striatal Cholinergic Synaptic Dysfunction by Interacting With GluN2D N-Methyl-D-Aspartate Receptor Subunit.
- Author
-
Tozzi, Alessandro, de Iure, Antonio, Bagetta, Vincenza, Tantucci, Michela, Durante, Valentina, Quiroga-Varela, Ana, Costa, Cinzia, Di Filippo, Massimiliano, Ghiglieri, Veronica, Latagliata, Emanuele Claudio, Wegrzynowicz, Michal, Decressac, Mickael, Giampà, Carmela, Dalley, Jeffrey W., Xia, Jing, Gardoni, Fabrizio, Mellone, Manuela, El-Agnaf, Omar Mukhtar, Ardah, Mustafa Taleb, and Puglisi-Allegra, Stefano
- Subjects
- *
PARKINSON'S disease & genetics , *ALPHA-synuclein , *DOPAMINERGIC neurons , *ASPARTATE receptors , *GENETIC overexpression , *BIOMARKERS - Abstract
Background Advanced Parkinson’s disease (PD) is characterized by massive degeneration of nigral dopaminergic neurons, dramatic motor and cognitive alterations, and presence of nigral Lewy bodies, whose main constituent is α-synuclein (α-syn). However, the synaptic mechanisms underlying behavioral and motor effects induced by early selective overexpression of nigral α-syn are still a matter of debate. Methods We performed behavioral, molecular, and immunohistochemical analyses in two transgenic models of PD, mice transgenic for truncated human α-synuclein 1-120 and rats injected with the adeno-associated viral vector carrying wild-type human α-synuclein. We also investigated striatal synaptic plasticity by electrophysiological recordings from spiny projection neurons and cholinergic interneurons. Results We found that overexpression of truncated or wild-type human α-syn causes partial reduction of striatal dopamine levels and selectively blocks the induction of long-term potentiation in striatal cholinergic interneurons, producing early memory and motor alterations. These effects were dependent on α-syn modulation of the GluN2D-expressing N -methyl-D-aspartate receptors in cholinergic interneurons. Acute in vitro application of human α-syn oligomers mimicked the synaptic effects observed ex vivo in PD models. Conclusions We suggest that striatal cholinergic dysfunction, induced by a direct interaction between α-syn and GluN2D-expressing N -methyl-D-aspartate receptors, represents a precocious biological marker of the disease. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
34. Derangement of Ras-Guanine Nucleotide-Releasing Factor 1 (Ras-GRF1) and Extracellular Signal-Regulated Kinase (ERK) Dependent Striatal Plasticity in L-DOPA-Induced Dyskinesia.
- Author
-
Cerovic, Milica, Bagetta, Vincenza, Pendolino, Valentina, Ghiglieri, Veronica, Fasano, Stefania, Morella, Ilaria, Hardingham, Neil, Heuer, Andreas, Papale, Alessandro, Marchisella, Francesca, Giampà, Carmela, Calabresi, Paolo, Picconi, Barbara, and Brambilla, Riccardo
- Subjects
- *
DYSKINESIAS , *EXTRACELLULAR signal-regulated kinases , *DOPA , *G proteins , *BASAL ganglia , *PHENOTYPIC plasticity , *THERAPEUTICS - Abstract
Background Bidirectional long-term plasticity at the corticostriatal synapse has been proposed as a central cellular mechanism governing dopamine-mediated behavioral adaptations in the basal ganglia system. Balanced activity of medium spiny neurons (MSNs) in the direct and the indirect pathways is essential for normal striatal function. This balance is disrupted in Parkinson’s disease and in l -3,4-dihydroxyphenylalanine ( l -DOPA)-induced dyskinesia (LID), a common motor complication of current pharmacotherapy of Parkinson’s disease. Methods Electrophysiological recordings were performed in mouse cortico-striatal slice preparation. Synaptic plasticity, such as long-term potentiation (LTP) and depotentiation, was investigated. Specific pharmacological inhibitors or genetic manipulations were used to modulate the Ras-extracellular signal-regulated kinase (Ras-ERK) pathway, a signal transduction cascade implicated in behavioral plasticity, and synaptic activity in different subpopulations of striatal neurons was measured. Results We found that the Ras-ERK pathway, is not only essential for long-term potentiation induced with a high frequency stimulation protocol (HFS-LTP) in the dorsal striatum, but also for its reversal, synaptic depotentiation. Ablation of Ras-guanine nucleotide-releasing factor 1 (Ras-GRF1), a neuronal activator of Ras proteins, causes a specific loss of HFS-LTP in the medium spiny neurons in the direct pathway without affecting LTP in the indirect pathway. Analysis of LTP in animals with unilateral 6-hydroxydopamine lesions (6-OHDA) rendered dyskinetic with chronic L-DOPA treatment reveals a complex, Ras-GRF1 and pathway-independent, apparently stochastic involvement of ERK. Conclusions These data not only demonstrate a central role for Ras-ERK signaling in striatal LTP, depotentiation, and LTP restored after L-DOPA treatment but also disclose multifaceted synaptic adaptations occurring in response to dopaminergic denervation and pulsatile administration of L-DOPA. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
35. Effects of central and peripheral inflammation on hippocampal synaptic plasticity
- Author
-
Di Filippo, Massimiliano, Chiasserini, Davide, Gardoni, Fabrizio, Viviani, Barbara, Tozzi, Alessandro, Giampà, Carmela, Costa, Cinzia, Tantucci, Michela, Zianni, Elisa, Boraso, Mariaserena, Siliquini, Sabrina, de Iure, Antonio, Ghiglieri, Veronica, Colcelli, Elisa, Baker, David, Sarchielli, Paola, Fusco, Francesca Romana, Di Luca, Monica, and Calabresi, Paolo
- Subjects
- *
NEUROLOGICAL disorders , *INFLAMMATION , *HIPPOCAMPUS (Brain) , *NEUROPLASTICITY , *IMMUNE system , *NEURAL circuitry , *ELECTROPHYSIOLOGY - Abstract
Abstract: The central nervous system (CNS) and the immune system are known to be engaged in an intense bidirectional crosstalk. In particular, the immune system has the potential to influence the induction of brain plastic phenomena and neuronal networks functioning. During direct CNS inflammation, as well as during systemic, peripheral, inflammation, the modulation exerted by neuroinflammatory mediators on synaptic plasticity might negatively influence brain neuronal networks functioning. The aim of the present study was to investigate, by using electrophysiological techniques, the ability of hippocampal excitatory synapses to undergo synaptic plasticity during the initial clinical phase of an experimental model of CNS (experimental autoimmune encephalomyelitis, EAE) as well as following a systemic inflammatory trigger. Moreover, we compared the morphologic, synaptic and molecular consequences of central neuroinflammation with those accompanying peripheral inflammation. Hippocampal long-term potentiation (LTP) has been studied by extracellular field potential recordings in the CA1 region. Immunohistochemistry was performed to investigate microglia activation. Western blot and ELISA assays have been performed to assess changes in the subunit composition of the synaptic glutamate NMDA receptor and the concentration of pro-inflammatory cytokines in the hippocampus. Significant microglial activation together with an impairment of CA1 LTP was present in the hippocampus of mice with central as well as peripheral inflammation. Interestingly, exclusively during EAE but not during systemic inflammation, the impairment of hippocampal LTP was paralleled by a selective reduction of the NMDA receptor NR2B subunit levels and a selective increase of interleukin-1β (IL1β) levels. Both central and peripheral inflammation-triggered mechanisms can activate CNS microglia and influence the function of CNS synapses. During direct CNS inflammation these events are accompanied by detectable changes in synaptic glutamate receptors subunit composition and in the levels of the pro-inflammatory cytokine IL1β. [Copyright &y& Elsevier]
- Published
- 2013
- Full Text
- View/download PDF
36. Rhes influences striatal cAMP/PKA-dependent signaling and synaptic plasticity in a gender-sensitive fashion
- Author
-
Valentina Pendolino, Maria Luisa Mancini, Massimo Pasqualetti, Carmela Giampà, Francesco Errico, Sara Migliarini, Chiara Schepisi, Robert Nisticò, Veronica Ghiglieri, Barbara Pelosi, Giacomo Maddaloni, Francesco Napolitano, Giuseppe Sciamanna, Alessandro Usiello, Anna Di Maio, Barbara Picconi, Daniela Vitucci, Ghiglieri, V, Napolitano, F, Pelosi, B, Schepisi, C, Migliarini, S, Di Maio, A, Pendolino, V, Mancini, M, Sciamanna, G, Vitucci, D, Maddaloni, G, Giampà, C, Errico, F, Nisticò, R, Pasqualetti, M, Picconi, B, Usiello, Alessandro, Ghiglieri, Veronica, Napolitano, Francesco, Pelosi, Barbara, Schepisi, Chiara, Migliarini, Sara, Di Maio, Anna, Pendolino, Valentina, Mancini, Maria, Sciamanna, Giuseppe, Vitucci, Daniela, Maddaloni, Giacomo, Giampà, Carmela, Errico, Francesco, Nisticò, Robert, Pasqualetti, Massimo, and Picconi, Barbara
- Subjects
Male ,Dopamine ,Long-Term Potentiation ,Messenger ,Gene Expression ,Hippocampus ,Striatum ,Mice ,Receptors ,Cyclic AMP ,GABAergic Neurons ,Mice, Knockout ,Neuronal Plasticity ,Multidisciplinary ,Cortical Spreading Depression ,Settore BIO/14 ,Long-term potentiation ,Settore MED/26 - NEUROLOGIA ,Female ,Receptor ,Signal Transduction ,medicine.drug ,medicine.medical_specialty ,Receptor, Adenosine A2A ,Knockout ,Motor Activity ,Biology ,Medium spiny neuron ,Article ,Adenosine A2A ,Sex Factors ,GTP-Binding Proteins ,Dopamine receptor D2 ,Internal medicine ,Dopamine D2 ,Neuroplasticity ,medicine ,Animals ,Humans ,RNA, Messenger ,Corpus Striatum ,Cyclic AMP-Dependent Protein Kinases ,Mutation ,Receptors, Dopamine D2 ,Endocrinology ,Rhes ,Synaptic plasticity ,RNA - Abstract
Mechanisms of gender-specific synaptic plasticity in the striatum, a brain region that controls motor, cognitive and psychiatric functions, remain unclear. Here we report that Rhes, a GTPase enriched in medium spiny neurons (MSNs) of striatum, alters the striatal cAMP/PKA signaling cascade in a gender-specific manner. While Rhes knockout (KO) male mice, compared to wild-type (WT) mice, had a significant basal increase of cAMP/PKA signaling pathway, the Rhes KO females exhibited a much stronger response of this pathway, selectively under the conditions of dopamine/adenosine-related drug challenge. Corticostriatal LTP defects are exclusively found in A2AR/D2R-expressing MSNs of KO females, compared to KO males, an effect that is abolished by PKA inhibitors but not by the removal of circulating estrogens. This suggests that the synaptic alterations found in KO females could be triggered by an aberrant A2AR/cAMP/PKA activity, but not due to estrogen-mediated effect. Consistent with increased cAMP signaling, D1R-mediated motor stimulation, haloperidol-induced catalepsy and caffeine-evoked hyper-activity are robustly enhanced in Rhes KO females compared to mutant males. Thus Rhes, a thyroid hormone-target gene, plays a relevant role in gender-specific synaptic and behavioral responses.
- Published
- 2015
37. Modulation of Phospho-CREB by Systemically Administered Recombinant BDNF in the Hippocampus of the R6/2 Mouse Model of Huntington's Disease.
- Author
-
Paldino E, Giampà C, Montagna E, Angeloni C, and Fusco FR
- Abstract
Huntington's disease (HD) is an autosomal dominant neurodegenerative disease due to an expansion of a trinucleotide repeats in IT15 gene encoding for the protein huntingtin. Motor dysfunction, cognitive decline, and psychiatric disorder are typical clinical signs of HD. In HD, mutated huntingtin causes a major loss of brain derived neurotrophic factor (BDNF), causing striatal atrophy. Moreover, a key involvement of BDNF was observed in the synaptic plasticity that controls the acquisition and/or consolidation of certain forms of memory. We studied changes in hippocampal BDNF and in CREB in the R6/2 mouse model of HD. Moreover, we investigated if the beneficial effects of systemically administered recombinant BDNF observed in the striatum and cortex had an effect also on the hippocampus. Osmotic minipumps that chronically released recombinant BDNF or saline solution from 4 weeks of age until euthanasia were implanted into R6/2 and wild type mice. Our data show that BDNF is severely decreased in the hippocampus of R6/2 mice, while BDNF treatment restored its physiological levels. Moreover, the chronic administration of recombinant BDNF promoted the increment of phosphorylated CREB protein. Our study demonstrates the involvement of hippocampus in the pathology of R6/2 model of HD and correlates the beneficial effects of BDNF administration with increased hippocampal levels of BDNF and pCREB.
- Published
- 2019
- Full Text
- View/download PDF
38. Persistent activation of microglia and NADPH oxidase [corrected] drive hippocampal dysfunction in experimental multiple sclerosis.
- Author
-
Di Filippo M, de Iure A, Giampà C, Chiasserini D, Tozzi A, Orvietani PL, Ghiglieri V, Tantucci M, Durante V, Quiroga-Varela A, Mancini A, Costa C, Sarchielli P, Fusco FR, and Calabresi P
- Subjects
- Animals, Encephalomyelitis, Autoimmune, Experimental enzymology, Encephalomyelitis, Autoimmune, Experimental pathology, Encephalomyelitis, Autoimmune, Experimental physiopathology, Enzyme Activation, Female, Mice, Behavior, Animal, CA1 Region, Hippocampal enzymology, CA1 Region, Hippocampal pathology, CA1 Region, Hippocampal physiopathology, Cognition, Long-Term Potentiation, Microglia enzymology, Microglia pathology, Multiple Sclerosis enzymology, Multiple Sclerosis pathology, Multiple Sclerosis physiopathology, NADPH Oxidases metabolism
- Abstract
Cognitive impairment is common in multiple sclerosis (MS). Unfortunately, the synaptic and molecular mechanisms underlying MS-associated cognitive dysfunction are largely unknown. We explored the presence and the underlying mechanism of cognitive and synaptic hippocampal dysfunction during the remission phase of experimental MS. Experiments were performed in a chronic-relapsing experimental autoimmune encephalomyelitis (EAE) model of MS, after the resolution of motor deficits. Immunohistochemistry and patch-clamp recordings were performed in the CA1 hippocampal area. The hole-board was utilized as cognitive/behavioural test. In the remission phase of experimental MS, hippocampal microglial cells showed signs of activation, CA1 hippocampal synapses presented an impaired long-term potentiation (LTP) and an alteration of spatial tests became evident. The activation of hippocampal microglia mediated synaptic and cognitive/behavioural alterations during EAE. Specifically, LTP blockade was found to be caused by the reactive oxygen species (ROS)-producing enzyme nicotinamide adenine dinucleotide phosphate (NADPH) oxidase. We suggest that in the remission phase of experimental MS microglia remains activated, causing synaptic dysfunctions mediated by NADPH oxidase. Inhibition of microglial activation and NADPH oxidase may represent a promising strategy to prevent neuroplasticity impairment associated with active neuro-inflammation, with the aim to improve cognition and counteract MS disease progression.
- Published
- 2016
- Full Text
- View/download PDF
39. Endogenous 17β-estradiol is required for activity-dependent long-term potentiation in the striatum: interaction with the dopaminergic system.
- Author
-
Tozzi A, de Iure A, Tantucci M, Durante V, Quiroga-Varela A, Giampà C, Di Mauro M, Mazzocchetti P, Costa C, Di Filippo M, Grassi S, Pettorossi VE, and Calabresi P
- Abstract
17β-estradiol (E2), a neurosteroid synthesized by P450-aromatase (ARO), modulates various brain functions. We characterized the role of the locally synthesized E2 on striatal long-term synaptic plasticity and explored possible interactions between E2 receptors (ERs) and dopamine (DA) receptors in the dorsal striatum of adult male rats. Inhibition of E2 synthesis or antagonism of ERs prevented the induction of long-term potentiation (LTP) in both medium spiny neurons (MSNs) and cholinergic interneurons (ChIs). Activation of a D1-like DA receptor/cAMP/PKA-dependent pathway restored LTP. In MSNs exogenous E2 reversed the effect of ARO inhibition. Also antagonism of M1 muscarinic receptors prevented the D1-like receptor-mediated restoration of LTP confirming a role for ChIs in controlling the E2-mediated LTP of MSNs. A novel striatal interaction, occurring between ERs and D1-like receptors in both MSNs and ChIs, might be critical to regulate basal ganglia physiology and to compensate synaptic alterations in Parkinson's disease.
- Published
- 2015
- Full Text
- View/download PDF
40. Phosphodiesterases as therapeutic targets for Huntington's disease.
- Author
-
Fusco FR and Giampà C
- Subjects
- Animals, Humans, Huntington Disease drug therapy, Huntington Disease enzymology, Phosphodiesterase Inhibitors therapeutic use, Phosphoric Diester Hydrolases chemistry
- Abstract
Huntington's disease (HD) is an autosomal-dominant inherited neurodegenerative disorder characterized by motor dysfunction, cognitive decline, and emotional and psychiatric disturbances. The genetic mutation is characterized by a CAG expansion, resulting in the formation of a mutant huntingtin protein with an expanded polyglutamine repeat region. Mutated huntingtin has been shown to impair a number of physiological activities by interacting with several factors. In particular, cAMP response element-binding protein (CREB) and brain-derived neurotrophic factor (BDNF) are severely affected by mutant huntingtin. In this view, drugs targeted at counteracting CREB loss of function and BDNF decrease have been considered as powerful tools to treat HD. Recently, cyclic nucleotide phosphodiesterase (PDE) inhibitors have been used successfully to increase levels of CREB and BDNF in HD models. Indeed, PDE4, 5 or 10 inhibitors have been shown to afford neuroprotection and modulation of CREB and BDNF. In this review, we will summarize the data supporting the use of PDE inhibitors as the therapeutical approach to fight HD and we will discuss the possible mechanisms of action underlying these effects.
- Published
- 2015
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.